In this thoughtfully designed and well-executed study, Moledina and colleagues provide a compelling argument for CXCL9 as a promising, noninvasive diagnostic biomarker in distinguishing AIN from other causes of AKI (8). This evidence concerns the gene CXCL9 and acute kidney injury.